Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

BOULDER, Colo., Oct. 3 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) announced today that it has initiated a Phase 2 open- label, multi-center study of TPI 287 in patients with advanced pancreatic cancer. This is the second Phase 2 trial exploring the activity of TPI 287 in various tumor types: the first Phase 2 trial began earlier this year in advanced hormone refractory prostate cancer.

"Currently available taxanes are not approved for pancreatic cancer and effective treatment options for this difficult tumor are quite limited," commented Leonard Shaykin, chairman and chief executive officer of Tapestry Pharmaceuticals. "This pancreatic trial, combined with our experience in both the Phase 1 and in the Phase 2 trial currently running in refractory prostate cancer, will further characterize the safety and efficacy profile of TPI 287 in classically resistant and hard to treat tumors."

Trial Design

The pancreatic cancer trial for TPI 287 is a multi-center, open-label, single arm Phase 2 study for up to 65 patients with advanced stage, unresectable pancreatic cancer who have failed a prior gemcitabine-containing chemotherapy regimen for their disease. The trial will be conducted in approximately 10 to 15 centers in the U.S., Europe and India. Patients will receive TPI 287 administered as a 60 minute (+/- 10 min) IV infusion.

The primary endpoint of the trial will be the six-month survival (percent of patients alive at six months after starting the study). Secondary efficacy endpoints will be the six-month progression free survival (percent of patients whose disease has not advanced by six months), response to therapy (reduction in radiographically measurable disease as d
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... For the pharmaceutical industry, marketplace success is tied to ... importance of the managed markets function - which is pharma,s ... payer formularies and provider networks play an increasingly large role ... time, managed markets leaders must continually identify the optimal resource ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ( ... Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and ... Video communication has been the topic of fascination since ... United States and the Soviet Russia. Earlier even ...
(Date:1/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) ... Market (Indwelling or Foley Catheters, Intermittent Catheters and Male ... Share, Growth, Trends and Forecast 2014 - 2020" ... present, the global market for urinary catheters is experiencing ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Biopure Corporation (Nasdaq: BPUR ) announced today ... 11 of the United States Bankruptcy Code in the United States ... to manage and operate its businesses and assets during the pendency ... Court. , , In connection with ...
... , , , SAN FRANCISCO, ... injuries and property damage from drywall imported from China is the ... July 28, 2009 at the Mission Bay Conference Center at the ... webcast. , , The conference producer, ...
... , , DETROIT, July 16 ... looking for alternative options to decrease spending without losing employee coverage. ... coverage for their employees and lower their costs by as much ... , , An HRA ...
... out, genes alone aren,t destiny, study finds , THURSDAY, ... behavior problems are influenced by both genetic and environmental ... research on genetic and environmental influences on behavior was ... professor of psychiatry, psychology, and human and molecular genetics ...
... higher risk of heart attack, stroke, agency says, , ... and Drug Administration has begun a safety review of ... increased risk of heart attack, abnormal heart rhythm, heart ... results from the Evaluating the Clinical Effectiveness and Long-Term ...
... NEW YORK and LOS ANGELES, July 16 "Back for a ... , with Benjamin Bratt starring as an ,extreme interventionist, a character ... What,s encouraging about The Cleaner is the exposure the ... With more than 23 million Americans misusing drugs these days, there,s ...
Cached Medicine News:Health News:Chinese Drywall Litigation & Insurance Conference July 28 in San Francisco 2Health News:How To Reduce Cost Without Sacrificing Your Health Coverage 2Health News:Teen Behaviors Stem From Genetics, Environment 2Health News:FDA Investigating Safety of Asthma Drug Xolair 2Health News:Coming Clean About The Cleaner - Phoenix House's Chief Clinical Officer David Deitch on Intervention, and the Recovery Process That Follows 2Health News:Coming Clean About The Cleaner - Phoenix House's Chief Clinical Officer David Deitch on Intervention, and the Recovery Process That Follows 3
Intrinsic Dual Chamber ICD With MVP Mode (Managed Ventricular Pacing). MVP promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular (RV) pacing to approximately...
... MULTI-LINK MINI VISION is Guidant's first cobalt ... the ML MINI VISION to have remarkably ... volume, thus creating a highly deliverable stent. ... for excellent outcomes in small vessel treatment. ...
... Intacs prescription inserts are an ophthalmologic medical ... of myopia from -1.00 to -3.00 diopters.* ... of the patient's central optical zone, the ... cornea. Intacs inserts is composed of two ...
... Heartline™ system is winning the hearts of ... "Remaining calm are the operative words for ... the same time they and their attending ... any change in their heart condition is ...
Medicine Products: